Xylitol not checked
Iperboreal Pharma Srl · IPX15 · IPX07
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- End Stage Renal Disease
- Main trialPhase 2
- “Prospective, randomized, controlled clinical trial. The aim is to compare the effects of the peritoneal dialysis solution IPX15, containing glucose (0.5%), xylitol (1.5%) and L-carnitine (0.02%) as osmotic agents (comparable to the standard 2.5% glucose PD solution), for the nocturnal exchange with the PD solution IPX07, containing glucose (0.5%), xylitol (0.7%) and L-carnitine (0.02%) as osmotic agents (comparable to the standard 1.5% glucose PD solution), for the diurnal (short dwell) exchanges. Planned total recruitment is 40 patients with stable end-stage renal disease (ESRD) treated by…”In the company’s words, NCT04001036 on ClinicalTrials.gov
- Other names
- IPX15 · IPX07
Other drugs for End Stage Renal Disease
- Migalastat HClAmicus Therapeutics · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
- TegoprubartEledon Pharmaceuticals · Phase 3
- SymvessHumacyte, Inc. · Phase 3
- RoxadustatAstellas · Phase 3
- RetatrutideEli Lilly · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Terminated | 30 Aug 2022 | Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026